CoGenesis® Drug Response
Pharmacogenomics for drug personalisation
A pharmacogenomics test (PGx) that shows how your genes affect drug metabolism. CoGenesis® Drug Response uses PGx to identify how your genes affect your response to common drugs. This helps doctors choose the right drug and dose for you.
- Patients being initiated on drugs where genetic variants may affect drug response or toxicity.
- Personalizing medication choice and dosage
- Reducing the risk of adverse drug reactions.
- Predicting non‑genetic drug responses (e.g., lifestyle factors).
- Predicting drug responses in the absence of established PGx guidelines from CPIC, DPWG, or the FDA.
| Step / Test | Accuracy | Notes |
|---|---|---|
| Variant calling – SNP | >99.9% | |
| Variant calling – Indel | >99% |
4mL peripheral blood (EDTA), 2mL saliva, 4 buccal swabs
Preferred sample type:
- 4mL Blood (EDTA tube),
- Codex-provided buccal swabs (4 swabs)
- Codex-provided saliva collection kit (2mL)
Saliva or buccal swab sample collection: Follow the enclosed instructions; do not eat, drink, or smoke for 30 minutes before collection.
- Insufficient DNA quantity or poor DNA quality
- Improperly labeled or contaminated samples
- Degraded specimens due to incorrect storage or transport
- Non-human samples or inappropriate specimen types
Samples must be collected and submitted by a licensed healthcare professional.
- Keep Blood samples at 4–8°C after collection; avoid freezing, deliver within 48 hours of collection.
- Saliva or buccal swabs are stability in room temperature for up to 7 days. Address: Unit 220, 2/F, Building 16W, HKSTP, Pak Shek Kok, NT, Hong Kong. Tel: +852 3008 2560
Please contact us for institutional pricing and ordering details.
Results guide clinicians in tailoring prescriptions for safety and effectiveness, with support from relevant CPIC, DPWG or FDA guidelines.
Pharmacogenomics (PGx) is the study of how genetic differences influence an individual’s response to medications. Variations in genes that encode drug‑metabolizing enzymes, transporters, and drug targets can significantly affect drug absorption, distribution, metabolism, and elimination. For example, polymorphisms in CYP450 enzymes (such as CYP2D6, CYP2C19, and CYP3A4) can lead to rapid, normal, or poor metabolism of many commonly prescribed drugs, including antidepressants, anticoagulants, and pain medications. CoGenesis® Drug Response provides clinically actionable insights by identifying patients at risk of adverse drug reactions. Guidelines from organizations such as CPIC (Clinical Pharmacogenetics Implementation Consortium), DPWG (Dutch Pharmacogenetics Working Group), and the FDA support the integration of PGx into clinical practice. By tailoring drug choice and dosage to a patient’s genetic profile, PGx may enable safer, more effective, and personalized treatment strategies, reducing trial‑and‑error prescribing and improving overall outcomes.
Hong Kong-based molecular diagnostics laboratory specialising in clinical genomics, precision oncology, and rare disease diagnosis. Accredited to ISO 27001 and GenQA standards.
© 2026 Codex Genetics Limited. All rights reserved.
